Dr. Bob Schenter believed the future of cancer treatment depended on one thing:

Access to isotopes.

He became fascinated with Alpha Emitters — especially Actinium-225 (Ac-225) — believing they had the potential to revolutionize targeted cancer therapy through highly precise radiation delivery.

As a co-scientist and early believer in Nusano’s technology, Dr. Schenter recognized the extraordinary potential of advanced accelerator systems and often said: “The beam could produce every isotope.”

He believed the ability to generate large-scale medical isotopes could eliminate shortages, expand research, and open the door to treatments once thought impossible.

To Dr. Schenter, Ac-225 was not simply another isotope.

It represented hope for the future of precision cancer therapy — and a new era in the fight against cancer.